Sarcoidosis Small-Fiber Neuropathy
ARA 290 is studied in small-fiber neuropathy models, including neuropathic symptom scores and physical-function measures in sarcoidosis research.
≥99% Purity
ARA-290
EPO-derived 11-mer · innate repair receptor agonist
$60.00$30.00/vial with BOGO
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
ARA-290 is also called cibinetide. It is a peptide made of 11 amino acids, taken from one section of erythropoietin. That is the hormone that drives red blood cell production. ARA-290 was designed to keep signalling at the innate repair receptor while leaving out the red blood cell effect. Research has measured its activity at that receptor, a two-part complex, and examined nerve and inflammation endpoints.
EPO helix-B surface derived 11-amino-acid peptide
- Formula
- C55H89N19O20
- Molecular weight
- 1257.3 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 1208243-50-8
0
Amino Acids
EPO helix-B derived peptide
0
Molecular Weight (Da)
C55H89N19O20
0+
Human Trials
sarcoidosis small-fiber neuropathy
0
Research Areas
Small-Fibre Neuropathy Models · Corneal & Skin Fibre Density · Long-Term Allodynia Thresholds & more
How It Works
How ARA-290 works
The pathways ARA-290 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
IRR (EPOR/CD131) Agonism
Innate Repair Receptor
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — a heterocomplex of the EPO receptor and the β-common receptor (CD131) — without engaging the classical receptor that drives red-cell production.
- Selective IRR (EPOR/βcR) agonism
- Non-erythropoietic — no effect on hematocrit
- Derived from EPO's helix-B surface domain
Resolution of Inflammation
Anti-Inflammatory
Through the innate repair receptor, lower pro-inflammatory signalling and markers of its resolution have been measured, alongside reduced collateral tissue damage in the same models.
- Suppresses pro-inflammatory cytokine signaling
- Shifts macrophages toward a reparative phenotype
- Suppresses spinal microglial activation in pain models
Cytoprotective & Neural Signalling
Survival Signalling
IRR activation engages JAK2/STAT3, PI3K/Akt and anti-apoptotic Bcl-2-family pathways, with cell survival and small-fibre measures recorded despite the peptide's very short plasma half-life.
- Activates JAK2/STAT3 & PI3K/Akt survival signaling
- Anti-apoptotic Bcl-2 family engagement
- Small-fibre density measured in research models
Uses & Applications
What ARA-290 is researched for
The main areas ARA-290 is being studied for — and the study-reported figures behind them.
Corneal & Skin Nerve Fibre Density
Over a 28-day exposure, neuropathic symptom scores and small-fibre measures were recorded, including corneal nerve fibre density.
Long-Term Allodynia Relief
In rodent models, mechanical and cold allodynia thresholds were recorded over 20 weeks alongside spinal microglia response, with a dose-dependent relationship reported.
EPO-Derived Cytoprotection
ARA 290 was engineered from EPO's tertiary structure to engage the innate repair receptor selectively, without the erythropoietic activity of native EPO.
Molecular Structure
The ARA-290 molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C55H89N19O20
Compound Information
Full specification
| Chemical Name | ARA-290 (Cibinetide) |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 aa) |
| Molecular Weight | 1,257.3 Da |
| Molecular Formula | C₅₅H₈₉N₁₉O₂₀ |
| CAS Number | 1208243-50-8 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Sterile or bacteriostatic water |
| COA | Included with every order |
FAQ
Common questions about ARA-290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). It was designed to engage the innate repair receptor selectively — without the red-blood-cell-stimulating activity of native EPO.
The IRR is a heterocomplex of the EPO receptor and the β-common receptor (CD131). It is the arm of EPO signalling distinct from the classical homodimeric EPO receptor that controls erythropoiesis. ARA-290 selectively activates it.
No. ARA-290 is non-erythropoietic — it does not engage the receptor pathway that drives red-cell production, so it does not raise hematocrit. That receptor separation is the central rationale behind its design.
ARA 290 is studied in models of small-fiber neuropathy, where the measures examined include neuropathic symptom scores, corneal nerve fiber density and small nerve fiber regrowth. Preclinical models also examine long-term neuropathic pain behaviors.
No. Research-grade ARA-290 sold here is strictly for in vitro laboratory research and analytical applications. It is not a drug and is not intended for human or veterinary use, consumption, or any clinical application.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.